16.8
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin…
A variety of CNS depressants are utilized as sedatives and hypnotics, each with distinct properties.
Melatonin congeners help treat insomnia and jet lag by mimicking melatonin's action in regulating sleep-wake cycles.
Chloral hydrate is used in pediatric medicine for its calming effects. Meprobamate, an anxiolytic, reduces brain activity to induce relaxation.
Etomidate and propofol are intravenous anesthetic agents, often used for induction and maintenance of anesthesia or sedation. They primarily act by potentiating GABAA receptor activity.
Clomethiazole, too, acts by enhancing GABAergic neurotransmission and helps manage alcohol withdrawal syndrome.
Suvorexant, an orexin receptor antagonist, promotes sleep.
Doxepin, a tricyclic antidepressant, treats insomnia by blocking histamine receptors at low doses.
Pregabalin binds to calcium channels, modulating calcium influx and inhibiting excitatory neurotransmitter release.
Newer agents include agomelatine, a serotonin-antagonizing melatonin agonist, and ritanserin, a serotonin antagonist.
View the full transcript and gain access to JoVE Core videos
Q1: How do melatonin congeners treat insomnia and jet lag?
Melatonin congeners like ramelteon and tasimelteon selectively bind to melatonin receptors (MT1 and MT2), mimicking melatonin's natural action in regulating sleep-wake cycles. These agents help restore normal sleep patterns in insomnia and jet lag by synchronizing circadian rhythms. Tasimelteon is also used for non-24-hour sleep-wake disorder in blind patients.
Q2: What is the mechanism of action for intravenous anesthetic agents like propofol and etomidate?
Propofol and etomidate are intravenous anesthetic agents that work primarily by potentiating GABAA receptor activity, enhancing inhibitory neurotransmission in the central nervous system. This potentiation reduces neuronal excitability, inducing rapid sedation and anesthesia suitable for induction and maintenance during procedures. Both agents carry risks of respiratory depression and hypotension.
Q3: How does suvorexant promote sleep differently from other sedative agents?
Suvorexant promotes sleep by blocking orexin receptors, which are neurotransmitters involved in wakefulness. Unlike agents that enhance inhibitory pathways, suvorexant directly suppresses the brain's arousal system. Common side effects include daytime sleepiness, headaches, and abnormal dreams, distinguishing its mechanism from traditional sedatives and hypnotics drugs barbiturates.
Q4: Why is doxepin used at low doses to treat insomnia?
Doxepin, a tricyclic antidepressant, treats insomnia by blocking histamine receptors at low doses, promoting sedation without triggering full antidepressant effects. At these lower concentrations, it increases norepinephrine levels while minimizing anticholinergic side effects like dry mouth, constipation, and urinary retention that occur at higher therapeutic doses.
Q5: What role does clomethiazole play in managing alcohol withdrawal syndrome?
Clomethiazole enhances GABAergic neurotransmission through the same mechanism as traditional barbiturates, providing sedative and anticonvulsant effects essential for managing alcohol withdrawal syndrome. Its ability to reduce neuronal excitability prevents seizures and agitation during withdrawal. However, clomethiazole carries risks of dependence and overdose, requiring careful monitoring.
Q6: How does pregabalin modulate neuronal activity to promote sedation?
Pregabalin modulates calcium channels and GABA receptors, reducing calcium influx and inhibiting excitatory neurotransmitter release in the central nervous system. This dual action decreases neuronal excitability, promoting relaxation and sedation. Dizziness is a common side effect associated with pregabalin use.
Q7: What are the differences between meprobamate and newer sedative agents?
Meprobamate is an anxiolytic that modulates GABAA receptors to reduce brain activity and induce relaxation, but it is rarely used today due to safer, more effective alternatives. Newer agents like agomelatine and ritanserin use serotonin-antagonizing mechanisms and are being studied for psychiatric applications. Meprobamate carries risks of drowsiness, dizziness, and rare thrombocytopenia.